Uveitis as an immune-related toxicity during checkpoint inhibitor immunotherapy

V. Kalinina Ayuso, J. Ossewaarde-van Norel, C. Kouwenberg, K. P. M. Suijkerbuijk, J. J. W. Kuiper, J. H. de Boer

Research output: Contribution to journalMeeting AbstractAcademic

Abstract

Purpose

To describe uveitis in patients treated with checkpoint inhibitors immune therapy for metastasized malignant melanoma.

Methods

Observational retrospective case series describing 6 patients with uveitis as an immune mediated toxicity during checkpoint inhibitor immune therapy in a single tertiary referral center in the Netherlands.

Results

In 2015–2018, six patients with uveitis as an immune‐related toxicity due to checkpoint inhibitor immune therapy for metastasized malignant melanoma have been identified. The age of patients varied between 45 and 71 years. Three of them received pembrolizumab and the other 3 patients received a combination of ipilimumab with nivolumab. The time to onset of uveitis after the initiation of the immune therapy varied between 2 days and 5 months with the most common onset between 2 and 3 months in 4/6 patients. In all patients, acute bilateral anterior uveitis was diagnosed with papillitis (3/6), subretinal fluid with subfoveal deposits (2/6) and cystoid macular edema (CME) (1/6). In 4/6 patients, uveitis was controlled with topical steroids. Two patients received additionally periocular steroid injections. In 5/6 patients a good control of inflammation was achieved with an excellent visual outcome. In one patient with persistent uveitis and CME despite topical and periocular treatment, anterior chamber tap cytology showed a predominantly T‐cel composition (86%).

Conclusions

Uveitis is a rare immune related toxicity of checkpoint inhibitor immune therapy which presents as an acute bilateral uveitis with good response to topical treatment and good visual prognosis. In refractory cases, complex therapeutic dilemma's can arise in these vulnerable patients.
Original languageEnglish
Pages (from-to)16-16
JournalActa Ophthalmologica
Volume97
Issue numberS262
Publication statusPublished - Mar 2019

Fingerprint

Dive into the research topics of 'Uveitis as an immune-related toxicity during checkpoint inhibitor immunotherapy'. Together they form a unique fingerprint.

Cite this